{"component": "definition", "props": {"groups": [{"samples": [{"hash": "5u1JG1Cs32z", "uri": "/contracts/5u1JG1Cs32z#key-products", "label": "Sale and Purchase Agreement (Glaxosmithkline PLC)", "score": 27.2094459534, "published": true}, {"hash": "aVpE8WRYQQI", "uri": "/contracts/aVpE8WRYQQI#key-products", "label": "Sale and Purchase Agreement (Novartis Ag)", "score": 26.0704994202, "published": true}, {"hash": "hOvHB3vXem4", "uri": "/contracts/hOvHB3vXem4#key-products", "label": "Sale and Purchase Agreement (Novartis Ag)", "score": 26.069814682, "published": true}], "size": 4, "snippet_links": [], "snippet": "means Tykerb, Promacta, Votrient, Arzerra, Tafinlar and Mekinist;", "hash": "74334cf5c19c638f353db7862edcf53b", "id": 1}, {"samples": [{"hash": "sIzZ24aca4", "uri": "/contracts/sIzZ24aca4#key-products", "label": "Merger Agreement (Pacific Biosciences of California, Inc.)", "score": 29.8432579041, "published": true}, {"hash": "fwiQJ4BZdJW", "uri": "/contracts/fwiQJ4BZdJW#key-products", "label": "Merger Agreement (Illumina Inc)", "score": 29.8432579041, "published": true}, {"hash": "dcSMG0IfbNL", "uri": "http://investor.pacificbiosciences.com/static-files/fbd95be9-53e8-4a83-bae6-fa31ccaa3f2d", "label": "investor.pacificbiosciences.com", "score": 10.1704311371, "published": false}], "size": 4, "snippet_links": [{"key": "the-company-disclosure-schedule", "type": "clause", "offset": [62, 93]}], "snippet": "means those products identified as such on Section 1.01(b) of the Company Disclosure Schedule.", "hash": "f3d1c370bf63068ff26e5f5c022934f4", "id": 2}, {"samples": [{"hash": "kib1OiCSWBv", "uri": "/contracts/kib1OiCSWBv#key-products", "label": "Merger Agreement (Amgen Inc)", "score": 22.6495552063, "published": true}, {"hash": "8X3YQMd6Izp", "uri": "/contracts/8X3YQMd6Izp#key-products", "label": "Merger Agreement (Onyx Pharmaceuticals Inc)", "score": 22.6495552063, "published": true}, {"hash": "8J5OTm4205x", "uri": "/contracts/8J5OTm4205x#key-products", "label": "Merger Agreement", "score": 20.8220405579, "published": true}], "size": 3, "snippet_links": [{"key": "products-of-the-company", "type": "clause", "offset": [10, 33]}], "snippet": "means the products of the Company known as \u201cKyprolis\u201d and \u201coprozomib\u201d.", "hash": "54c010fe3d88859d2f0cf5046568e5a5", "id": 3}, {"samples": [{"hash": "1pm6zu9EEGT", "uri": "/contracts/1pm6zu9EEGT#key-products", "label": "Facility Agreement (BeiGene, Ltd.)", "score": 34.9404525757, "published": true}, {"hash": "gJo8MmlXm2C", "uri": "/contracts/gJo8MmlXm2C#key-products", "label": "Facility Agreement (BeiGene, Ltd.)", "score": 33.5824775696, "published": true}, {"hash": "85dfv34ejPq", "uri": "https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1210/2024121001080.pdf", "label": "www1.hkexnews.hk", "score": 19.6688556671, "published": false}], "size": 3, "snippet_links": [], "snippet": "means, collectively, the following medicines:", "hash": "6b686b25edc237a9f19228d257c2f2ee", "id": 4}, {"samples": [{"hash": "cdD49yXwXo4", "uri": "/contracts/cdD49yXwXo4#key-products", "label": "Merger Agreement (Shire Pharmaceutical Holdings Ireland Ltd.)", "score": 26.0294322968, "published": true}, {"hash": "8O46sAqBeKY", "uri": "/contracts/8O46sAqBeKY#key-products", "label": "Merger Agreement (NPS Pharmaceuticals Inc)", "score": 26.0294322968, "published": true}], "size": 2, "snippet_links": [{"key": "trade-name", "type": "definition", "offset": [90, 100]}, {"key": "in-the-united-states", "type": "clause", "offset": [109, 129]}], "snippet": "means (i) teduglutide, (ii) parathyroid hormone (1-84) (which would be marketed under the trade name Natpara in the United States and Natpar in Europe) and (iii) NPSP795.", "hash": "8ec2369c096cae5805c7e930016efbd2", "id": 5}, {"samples": [{"hash": "7GOOdkC7FwK", "uri": "/contracts/7GOOdkC7FwK#key-products", "label": "Merger Agreement (Shire PLC)", "score": 24.8631076813, "published": true}, {"hash": "2vnlMS26YIO", "uri": "/contracts/2vnlMS26YIO#key-products", "label": "Merger Agreement (Viropharma Inc)", "score": 24.8631076813, "published": true}], "size": 2, "snippet_links": [{"key": "the-products", "type": "clause", "offset": [10, 22]}, {"key": "low-volume", "type": "definition", "offset": [67, 77]}, {"key": "the-non", "type": "clause", "offset": [212, 219]}], "snippet": "means (a) the products known as Cinryze (including any alternative low volume formulation of Cinryze or any formulation utilizing subcutaneous administration), Plenadren, Buccolam, Vancocin and Maribavir and (b) the non-toxigenic strain of C. difficile (VP20621) and any products containing such strain;", "hash": "50642e83657b54bd2e1774500a3b7046", "id": 6}, {"samples": [{"hash": "fer42lgyAZd", "uri": "/contracts/fer42lgyAZd#key-products", "label": "Merger Agreement (King Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "2ItBz1Zj38X", "uri": "/contracts/2ItBz1Zj38X#key-products", "label": "Merger Agreement (Mylan Laboratories Inc)", "score": 18.0, "published": true}], "size": 2, "snippet_links": [{"key": "products-of-the-company", "type": "clause", "offset": [10, 33]}, {"key": "line-extensions", "type": "clause", "offset": [61, 76]}, {"key": "company-disclosure-letter", "type": "definition", "offset": [112, 137]}], "snippet": "means the products of the Company and certain expansions and line extensions set forth in Section 8.3(s) of the Company Disclosure Letter;", "hash": "eb6ad9823dadc31a2c8a8062851efb45", "id": 7}, {"samples": [{"hash": "hEpPn8nDvHE", "uri": "/contracts/hEpPn8nDvHE#key-products", "label": "Merger Agreement (Segue Software Inc)", "score": 21.0, "published": true}, {"hash": "365RzH1nhWz", "uri": "/contracts/365RzH1nhWz#key-products", "label": "Merger Agreement (Borland Software Corp)", "score": 21.0, "published": true}], "size": 2, "snippet_links": [{"key": "performance-manager", "type": "definition", "offset": [471, 490]}, {"key": "the-foregoing", "type": "definition", "offset": [520, 533]}, {"key": "without-limitation", "type": "clause", "offset": [546, 564]}, {"key": "the-development", "type": "clause", "offset": [583, 598]}, {"key": "testing-phase", "type": "clause", "offset": [602, 615]}], "snippet": "means the following Products: SilkTest (including Runtime and Add-ons), SilkTest International, SilkPerformer (including Protocols/Interface Add-ons), SilkPerformer Virtual Users, SilkPerformer Workbench (MMC), SilkPerformer Developer Workbench, SilkPerformer Java Explorer, SilkPerformer .NET Explorer, SilkPerformer Server Analysis Module (\u2587\u2587\u2587), SilkPerformer Lite, SilkPerformer Component Test Edition, SilkCentral Test Manager, SilkCentral Issue Manager, SilkCentral Performance Manager, and any component of any of the foregoing, including, without limitation, any component in the development or testing phase.", "hash": "a12cb7c0e068e893254a6e48541c93e3", "id": 8}, {"samples": [{"hash": "kgve3KI3q4a", "uri": "/contracts/kgve3KI3q4a#key-products", "label": "Merger Agreement (Sucampo Pharmaceuticals, Inc.)", "score": 28.9835720062, "published": true}, {"hash": "jy0xwcn71Bf", "uri": "/contracts/jy0xwcn71Bf#key-products", "label": "Merger Agreement (Mallinckrodt PLC)", "score": 28.9835720062, "published": true}], "size": 2, "snippet_links": [{"key": "and-the-company", "type": "clause", "offset": [103, 118]}, {"key": "product-candidates", "type": "definition", "offset": [121, 139]}], "snippet": "means, collectively, the Company\u2019s products AMITIZA (lubiprostone) and RESCULA (unoprostone isopropyl) and the Company\u2019s product candidates VTS-270 and CPP-1X.", "hash": "dc79be279096d19bb125d76eb4b9880d", "id": 9}, {"samples": [{"hash": "erVAjBP3vjX", "uri": "/contracts/erVAjBP3vjX#key-products", "label": "Merger Agreement (Gilead Sciences Inc)", "score": 28.6550312042, "published": true}, {"hash": "NIhOcA9znZ", "uri": "/contracts/NIhOcA9znZ#key-products", "label": "Agreement and Plan of Merger (Kite Pharma, Inc.)", "score": 28.6550312042, "published": true}], "size": 2, "snippet_links": [{"key": "the-company", "type": "clause", "offset": [6, 17]}, {"key": "product-candidate", "type": "definition", "offset": [20, 37]}], "snippet": "means the Company\u2019s product candidate axicabtagene ciloleucel, KITE-718 and KITE-585.", "hash": "73c52672c92449cb15141f8de3dac32c", "id": 10}], "next_curs": "ClkSU2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjULEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIVa2V5LXByb2R1Y3RzIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 46, "title": "Key Products", "snippet": "means Tykerb, Promacta, Votrient, Arzerra, Tafinlar and Mekinist;", "id": "key-products", "examples": ["To the Seller\u2019s Knowledge, all Patents forming part of Registered Business Product Intellectual Property Rights for the <strong>Key Products</strong> and all Patents forming part of Registered Licensed Product Intellectual Property Rights for the <strong>Key Products</strong> are subsisting, valid and enforceable and have not lapsed or been abandoned.", "As of the date hereof, no, director, officer or other Affiliate of the Seller or any of its Subsidiaries or any of such Person\u2019s Affiliates, or any entity in which any such Person has a direct or indirect material interest, (a) has any right, title, or interest in any <strong>Key Products</strong> IP Rights or (b) is party to or bound by any Purchased Contract.", "Nothing in this Section 4.6(b) shall be deemed to permit the disclosure by the Seller or any of its Affiliates of any Trade Secrets concerning the <strong>Key Products</strong> or the other Purchased Assets.", "Neither Parent nor Purchaser shall be obligated to offer employment to the <strong>Key Products</strong> Employees set forth in Section 2.10(a)(ii) of the Seller Disclosure Schedule.", "Section 2.10(a) of the Seller Disclosure Schedule identifies any <strong>Key Products</strong> Employees who are on short-term disability or other approved leave of absence (other than vacation), their anticipated return to work date and the Seller Plans in which they participate in or may be entitled to benefits.", "Once selected or assigned all runs must be driven for at least four (4) weeks except that any driver may bid on any posted run.", "Except as set forth in Section 2.16(b) of the Seller Disclosure Schedule, no <strong>Key Products</strong> IP Rights is subject to any outstanding decree, order, injunction, judgment or ruling restricting the use of such Intellectual Property Right or that would impair the validity or enforceability of such Intellectual Property Right.", "No Person has asserted by way of allegation, cease and desist demands, unsolicited offers of license or otherwise or, to the Seller\u2019s Knowledge, has the right to assert any claim regarding the use of, or challenging or questioning the Seller\u2019s right or title in, any of the <strong>Key Products</strong> IP Rights.", "The Purchased Assets, include all of the assets, rights and properties (including Intellectual Property Rights) of the Seller and its Subsidiaries related to the operation of the Boulder Facilities and that are used or held for use for the manufacture or development of <strong>Key Products</strong>.", "No Actions have been brought or threatened against any Person during the past six (6) years, with respect to any Company Intellectual Property relating to any or all of the <strong>Key Products</strong>, or during the past three (3) years, with respect to any other Company Intellectual Property, by the Company, any of its Subsidiaries or, with respect to any or all of the <strong>Key Products</strong>, by any of their licensors and, to the Knowledge of the Company, there is no basis for any Action regarding any of the foregoing."], "related": [["third-party-products", "Third Party Products", "Third Party Products"], ["hemp-products", "Hemp products", "Hemp products"], ["new-products", "New Products", "New Products"], ["end-products", "End Products", "End Products"], ["cannabis-products", "Cannabis products", "Cannabis products"]], "related_snippets": [], "updated": "2025-12-11T04:24:21+00:00"}, "json": true, "cursor": ""}}